These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 37389109)

  • 21. A patient-centered, multidisciplinary approach to treating borderline resectable pancreatic adenocarcinoma.
    Hester CA; Katz MHG
    Chin Clin Oncol; 2022 Dec; 11(6):45. PubMed ID: 36509553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?
    Vivarelli M; Mocchegiani F; Nicolini D; Vecchi A; Conte G; Dalla Bona E; Rossi R; Benedetti Cacciaguerra A
    Front Oncol; 2022; 12():914203. PubMed ID: 35712487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy.
    van Dam MA; Vuijk FA; Stibbe JA; Houvast RD; Luelmo SAC; Crobach S; Shahbazi Feshtali S; de Geus-Oei LF; Bonsing BA; Sier CFM; Kuppen PJK; Swijnenburg RJ; Windhorst AD; Burggraaf J; Vahrmeijer AL; Mieog JSD
    Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma.
    Sardar M; Recio-Boiles A; Mody K; Karime C; Chandana SR; Mahadevan D; Starr J; Jones J; Borad M; Babiker H
    Expert Opin Pharmacother; 2022 Dec; 23(18):2079-2089. PubMed ID: 36394449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going.
    Coppola A; Farolfi T; La Vaccara V; Iannone I; Giovinazzo F; Panettieri E; Tarallo M; Cammarata R; Coppola R; Caputo D
    J Clin Med; 2023 May; 12(11):. PubMed ID: 37297872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives.
    de Scordilli M; Michelotti A; Zara D; Palmero L; Alberti M; Noto C; Totaro F; Foltran L; Guardascione M; Iacono D; Ongaro E; Fasola G; Puglisi F
    Crit Rev Oncol Hematol; 2023 Jun; 186():104013. PubMed ID: 37116817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.
    Klaiber U; Leonhardt CS; Strobel O; Tjaden C; Hackert T; Neoptolemos JP
    Langenbecks Arch Surg; 2018 Dec; 403(8):917-932. PubMed ID: 30397779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
    Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
    Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma.
    Lekka K; Tzitzi E; Giakoustidis A; Papadopoulos V; Giakoustidis D
    Ann Hepatobiliary Pancreat Surg; 2019 May; 23(2):97-108. PubMed ID: 31225409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer.
    Chawla A; Molina G; Pak LM; Rosenthal M; Mancias JD; Clancy TE; Wolpin BM; Wang J
    Ann Surg Oncol; 2020 Apr; 27(4):1191-1200. PubMed ID: 31802297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Borderline resectable pancreatic cancer.
    Hackert T; Ulrich A; Büchler MW
    Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Surgical Concepts and Future Perspectives in the Treatment of Borderline Resectable and Potentially Resectable Locally Advanced Pancreatic Cancer.
    Karamarković AR; Juloski JT
    Chirurgia (Bucur); 2022 Jun; 117(4):385-398. PubMed ID: 36049095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?
    Glynne-Jones R; Grainger J; Harrison M; Ostler P; Makris A
    Br J Cancer; 2006 Feb; 94(3):363-71. PubMed ID: 16465172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
    Mavros MN; Moris D; Karanicolas PJ; Katz MHG; O'Reilly EM; Pawlik TM
    JAMA Surg; 2021 Jul; 156(7):663-672. PubMed ID: 33787841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis.
    Yoo C; Shin SH; Kim KP; Jeong JH; Chang HM; Kang JH; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Ryoo BY; Kim SC
    Cancers (Basel); 2019 Feb; 11(3):. PubMed ID: 30813624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
    Schwarz L; Vernerey D; Bachet JB; Tuech JJ; Portales F; Michel P; Cunha AS
    BMC Cancer; 2018 Jul; 18(1):762. PubMed ID: 30041614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies.
    Pecorelli N; Licinio AW; Guarneri G; Aleotti F; Crippa S; Reni M; Falconi M; Balzano G
    Front Oncol; 2021; 11():812102. PubMed ID: 35083158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.